Alert detail
FDA Approval: INLURIYO (IMLUNESTRANT) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA218881Specialty: OncologyAdded: 9/23/2026Effective: September 25, 2025federal register
What changed
Oral ER antagonist Inluriyo routes through Medicare Part D pharmacy benefit.
Who’s affected: Oncology billing teams · Effective: September 25, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.